Virica Biotech and FUJIFILM Biosciences Team Up to Advance AAV Production Enhancers Through Canada–Japan Co-Innovation Initiative
Virica Biotech, a biotechnology firm focused on improving viral vector manufacturing through its proprietary Viral Sensitizer Enhancer (VSE™) technology, has announced a new international collaboration with FUJIFILM Biosciences. The partnership is being supported through advisory services and funding from the National Research Council of Canada Industrial Research Assistance Program under the Canada–Japan Corporate Co-Innovation Program, highlighting the growing importance of cross-border innovation in advancing next-generation biomanufacturing solutions.
The collaboration is centered on optimizing a tailored VSE™ formulation designed to work in combination with FUJIFILM Biosciences’ BalanCD HEK293 media system. The goal is to enhance the production efficiency of adeno-associated virus (AAV) vectors, which are widely used as delivery vehicles in gene therapy. AAV vectors have become a cornerstone of in vivo gene delivery due to their favorable safety profile and ability to target a wide range of tissues. However, despite their clinical promise, AAV vectors remain notoriously difficult and expensive to manufacture at scale, posing a significant bottleneck for the broader adoption of gene therapies.
As the pipeline of gene therapies continues to expand into more disease areas and larger patient populations, the demand for high-quality AAV vectors is increasing rapidly. At the same time, the economic pressures associated with producing these therapies—particularly cost-of-goods considerations—are intensifying. Current manufacturing approaches often struggle to deliver the yield, consistency, and scalability required to meet both clinical and commercial demands. This challenge has created an urgent need for innovative solutions that can improve productivity while maintaining product quality.
The partnership between Virica Biotech and FUJIFILM Biosciences seeks to address these challenges by combining complementary expertise and technologies. Virica’s VSE™ platform is designed to enhance viral vector production by modulating cellular responses that typically limit virus yield. By sensitizing cells to viral production processes, VSE™ technology can significantly increase the efficiency of vector manufacturing. Meanwhile, FUJIFILM Biosciences brings deep expertise in cell culture media development, including its BalanCD HEK293 system, which is widely used for suspension-based cell culture processes in viral vector production.
The joint effort will focus on optimizing both the formulation of the VSE™ enhancer and the associated process parameters for AAV production using suspension HEK293 cells grown in BalanCD media. This work will leverage Virica’s advanced High-Throughput Virology (HTV™) platform, which enables rapid screening and optimization of production conditions. In addition, the collaboration will utilize Design-of-Experiments (DoE) methodologies to systematically evaluate the impact of different variables on AAV yield and quality. Analytical testing will also play a key role in validating the performance of the optimized system.
FUJIFILM Biosciences will contribute its extensive knowledge in media formulation, feed strategies, and process scale-up, ensuring that the optimized solution is not only effective at the laboratory scale but also translatable to commercial manufacturing environments. By integrating these capabilities, the collaboration aims to deliver a robust and scalable solution that can be readily adopted by both academic and commercial AAV producers.
One of the key objectives of the project is to create an off-the-shelf enhancer–media combination that simplifies implementation for end users. Rather than requiring extensive process redevelopment, the optimized solution is intended to be compatible with existing workflows, enabling manufacturers to achieve productivity gains with minimal disruption. This approach is particularly valuable in the fast-moving field of gene therapy, where time-to-market and operational efficiency are critical factors.
Dr. Jean-Simon Diallo, scientific co-founder and Chief Executive Officer of Virica Biotech, highlighted the strategic alignment between the two organizations. He noted that the combination of Virica’s VSE™ technology with FUJIFILM Biosciences’ BalanCD media portfolio represents a strong opportunity to drive meaningful improvements in AAV production. Diallo also referenced the recent launch of Virica’s CellVantage™ AAV enhancer, emphasizing the company’s ongoing commitment to developing solutions that deliver tangible productivity gains for viral vector manufacturers.
According to Diallo, the collaboration aims to build on this foundation by creating a formulation specifically optimized for the BalanCD HEK293 system. This targeted approach is expected to unlock additional performance improvements, further enhancing the efficiency and scalability of AAV manufacturing processes.
Yutaka Yamaguchi, Chairman and Chief Executive Officer of FUJIFILM Biosciences, also underscored the importance of the partnership. He emphasized the company’s commitment to providing integrated solutions that combine high-performance media with enabling technologies. By optimizing Virica’s VSE-based enhancers within the BalanCD HEK293 system, FUJIFILM Biosciences aims to offer customers a practical and easy-to-implement option for improving AAV yields and supporting efficient scale-up.
The involvement of NRC IRAP through the Canada–Japan Corporate Co-Innovation Program further reinforces the significance of this initiative. By providing funding and advisory support, the program is helping to facilitate collaboration between Canadian and Japanese organizations, fostering innovation that addresses global challenges in biomanufacturing. Such partnerships are increasingly important as the life sciences industry seeks to overcome technical and economic barriers to the widespread adoption of advanced therapies.
The successful development of an optimized VSE™-media combination could have far-reaching implications for the gene therapy field. Improved AAV production efficiency would not only reduce manufacturing costs but also increase the availability of therapies for patients. This is particularly important as gene therapies move beyond rare diseases into more prevalent conditions, where large-scale production becomes essential.
In addition to supporting commercial manufacturing, the optimized solution is expected to benefit academic researchers and smaller biotechnology companies, which often face resource constraints when developing and producing viral vectors. By providing a ready-to-use system that enhances productivity without requiring extensive process development, the collaboration could help democratize access to advanced manufacturing technologies.
Overall, the partnership between Virica Biotech and FUJIFILM Biosciences represents a strategic effort to address one of the most pressing challenges in the gene therapy industry. By combining innovative cell enhancement technologies with advanced media systems, the collaboration aims to deliver a scalable, efficient, and user-friendly solution for AAV production. With support from NRC IRAP, this initiative underscores the power of international collaboration in driving innovation and advancing the future of cell and gene therapy manufacturing.
About Virica Biotech
Virica develops cell enhancers that improve the yield and quality of viral vectors used for cell & gene therapies and vaccines, allowing developers to deploy their products at scale economically. Virica’s Viral Sensitizer (VSE™) enhancers reduce production inefficiencies caused by cellular defenses in manufacturing cells. Purpose-formulated VSE combinations substantially increase manufacturing yields and reduce the cost of goods for a range of products. Beyond supplying VSEs as off-the-shelf reagents, Virica operates as a fast-turnaround service partner. Our proprietary High-Throughput Virology (HTV™) platform, Design-of-Experiments (DoE) process optimization, and analytical testing workflows enable developers to rapidly pinpoint the optimal transfection or transduction conditions, allowing programs to scale sooner and at a lower cost.
About FUJIFILM Biosciences
With a foundation in cell culture that dates back to 1970, FUJIFILM Biosciences is a global, full spectrum supplier to the life sciences market, providing products and services that assist customers in advancing healthcare initiatives. With an expanding portfolio of applications supported that include life science and discovery research, cell and gene therapy, as well as the large-scale production of biotherapeutics and vaccines, the Company is trusted by researchers and manufacturers worldwide. For over 50 years, FUJIFILM Biosciences’ Mission has been to empower all who bring medicines and treatments to life with unmatched quality and responsiveness in its products and custom solutions, providing customers with the vital resources needed to enrich human lives through innovative, accessible therapies.
The Company’s facilities adhere to both ISO and FDA regulations, with manufacturing facilities that follow cGMP guidelines in the USA, Japan, and the Netherlands, and a media optimization center in China. All sites prioritize strategies that adhere to the FUJIFILM Sustainability Value Plan 2030 for sustainable growth. FUJIFILM Biosciences operates as a subsidiary of FUJIFILM Holdings America Corporation under FUJIFILM Holdings Corporation.
Source Link:https://www.businesswire.com/
